{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-24-000054","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.825968+00:00","generated_at":"2026-05-31T20:30:06.479342+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Caribou discontinues CAR-NK platform, cuts 12% workforce to extend cash runway into H2 2026","bullets":["Preliminary cash $311.8M at June 30, 2024; expects to report Q2 results later.","Discontinues allogeneic CAR-NK preclinical research; focuses on CAR-T cell therapy and four clinical programs.","Workforce reduction of 21 positions (~12%); expects to complete by end of Q3 2024.","Estimated severance costs $0.5M–$1.0M in Q3 2024.","Cash runway extended at least 6 months into H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-24-000054","json":"https://secwatch.observer/filing/0001619856-24-000054.json","markdown":"https://secwatch.observer/filing/0001619856-24-000054.md","text":"https://secwatch.observer/filing/0001619856-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/0001619856-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:30:06.479342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}